.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

EP. 1: The Complexity of HCC Multidisciplinary Management

October 30th 2020

EP. 2: Screening Vs Diagnosis: Assessing Liver Function

October 30th 2020

EP. 3: The BCLC Staging System

October 30th 2020

EP. 4: The TACE Approach for Intermediate-Stage Disease

October 30th 2020

EP. 5: Optimal HCC Frontline Treatments

October 30th 2020

EP. 6: Choosing a Frontline Therapy

October 30th 2020

EP. 7: NCCN Guidelines: Nivolumab in Frontline Setting

October 30th 2020

EP. 8: Importance of Endoscopy in Newly Diagnosed HCC

October 30th 2020

EP. 9: Promising Ongoing Frontline Trials

October 30th 2020

EP. 10: Second-Line Options After IMbrave150 Regimen

October 30th 2020

EP. 11: Immunotherapy Monotherapy in Later-Line Setting

October 30th 2020

EP. 12: High AFP as Deciding Factor for Treatment

October 30th 2020

EP. 13: Developing Trial Regimens for Chinese Populations

October 30th 2020

EP. 14: Evolving HCC Treatment Landscape: Combination Therapy

October 30th 2020